SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq-100 selloff has traders focused on heavyweight tech earnings and concerns that soaring AI spending may not deliver returns fast enough, with some attributing added pressure to month-end liquidation and margin calls. The community is split between fears of a deeper AI-led correction and dip buyers looking for a rebound.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook, citing soft PC demand and manufacturing constraints, has driven a steep selloff, with analyst downgrades adding pressure. Traders are split between calling the drop an overreaction and buying the dip versus warning of further downside, while some see the move as part of a broader tech and semiconductor rout.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp, tech-led market selloff has put SPY in focus, with traders connecting the pressure to Amazon and Intel results and renewed concerns that heavy AI spending may not pay off. The discussion is largely bearish, with crash and liquidation fears competing against calls to buy the dip and expectations of a relief bounce.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

A broad tech and semiconductor selloff has weighed on Nvidia, as concerns about Big Techs heavy AI infrastructure spending and uncertain returns are compounded by fallout from Amazon and Intel results. Traders are divided between warning that the AI trade is a bubble and viewing the decline as an overreaction or buying opportunity, with some arguing AI demand remains intact.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is under pressure amid a broad semiconductor and tech selloff, with traders repeatedly pointing to Intels weak outlook and softer PC demand as a drag on chip sentiment, alongside concerns about AI valuations. Its 3x leverage magnifies the downturn; the community is split between dip buyers anticipating a rebound and bears warning of further losses and leverage decay.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is selling off sharply despite a strong quarterly beat, upbeat guidance and an announced 8-for-1 split, as traders debate whether the drop reflects a broader tech and AI-stock unwind or concerns that memory pricing and earnings growth are nearing a cyclical peak. Many call the decline an overreaction and are buying the dip, while bears point to slowing growth and possible peak-cycle risks.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares plunged after its quarterly report paired strong results with a weaker-than-expected outlook, declining Google search referrals and signs of slowing user growth; plans to push users toward a logged-in experience added concern about traffic and ad reach. Traders are split between calling the selloff an overreaction given Reddits growth and profitability, and warning that search dependence and potential user losses threaten future growth.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broad technology and semiconductor selloff as investors question AI spending returns and elevated chip valuations, with Intels weak outlook adding to sector pressure. Traders disagree over whether AMDs decline is justified or sympathy selling ahead of its earnings report, citing its data-center opportunity as a counterpoint.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its earnings report is driving discussion, with traders pointing to analyst price-target cuts and concerns about ad-tech peers results and the broader market. Bulls argue the decline has made the companys valuation compelling, while bears fear weak results or guidance could bring further pressure.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins selloff is being linked mainly to a reported major Binance security breach, with traders also citing leveraged liquidations and weakness in tech stocks as added pressure. The community is split between fears of further selling and exchange-related security risks, and dip-buyers arguing the incident affected Binance rather than Bitcoin itself and that the price has held up relatively well.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx Sales

Exelixis tops Q3 2026 earnings and revenue estimates as Cabometyx sales grow, share repurchases accelerate and its zanzalintinib pipeline advances.

Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop

Investors who lost money on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the Company may...

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth

AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.

Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook

MRK raises its 2026 outlook as KEYTRUDA demand, newer medicines and oncology pipeline breakthroughs support growth despite looming patent and generic pressures.

Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline

Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the...

Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 1.76% Stock Decline

Merck & Co., Inc. ("Merck" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Merck & Co., Inc. (NYSE: MRK), examining whether the...

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up

Merck's Q3 earnings and sales beat estimates as Keytruda and newer products drive growth, prompting the company to raise its 2026 earnings outlook.

Merck (MRK) Surpasses Q3 Earnings and Revenue Estimates

Merck (MRK) delivered earnings and revenue surprises of +17.45% and +4.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2026. Our science-led strategy is transforming our business, said Robert M. Davis, chairman and chief executive officer. The potentially...

$MRK Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $2.49 down -3.49% YoY
• Reported revenue of $18.09B up 4.68% YoY
• Merck &amp; Co. raised and narrowed full-year 2026 sales outlook to $66.8B to $67.3B and non-GAAP EPS outlook to $2.77 to $2.82, including one-time SciBrunch charge.

Stocktwits

Merck & Co Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $2.49 down -3.49% YoY
• Reported revenue of $18.09B up 4.68% YoY
• Merck & Co. raised and narrowed full-year 2026 sales outlook to $66.8B to $67.3B and non-GAAP EPS outlook to $2.77 to $2.82, including one-time SciBrunch charge.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of $2.49 down -3.49% YoY
• Reported revenue of $18.09B up 4.68% YoY
• Merck & Co. raised and narrowed full-year 2026 sales outlook to $66.8B to $67.3B and non-GAAP EPS outlook to $2.77 to $2.82, including one-time SciBrunch charge.

Merck & Co. reported lower GAAP gross margin and non-GAAP EPS year over year, alongside JANUVIA/JANUMET sales declines tied to generic competition following loss of U.S. market exclusivity.

Merck & Co. recorded growth in KEYTRUDA/KEYTRUDA QLEX and WINREVAIR sales, while Phase 3 INTerpath-001 results showed intismeran plus KEYTRUDA reduced recurrence-or-death risk by 42% versus KEYTRUDA alone.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck’s Endometrial Cancer Drug Cuts Risk Of Death By 32% – FDA Decision Due By June 2027

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The treatment reduced the risk of cancer progression or death by 41%.</li><li>The U.S. FDA accepted Merck’s application for priority review</li><li>The FDA set June 15, 2027 as the deadline to approve the drug.</li></ul>Merck (MRK), on Monday, reported that Phase 3 of its experimental cancer drug Sacituzumab Tirumotecan (Sac-TMT) helped patients with advanced or recurrent endometrial cancer live longer than those receiving just chemotherapy.The results were presented at the European Society for Medical Oncology (ESMO) Congress 2026, alongside new findings for Merck’s blockbuster cancer treatment Keytruda.<a class="mention" data-mention="$MRK" data-symbol-id="MRK" href="https://stocktwits.com/symbol/MRK" target="_blank">MRK shares</a> traded 3% lower at the time of writing and were tracking their third straight session of losses.<h2 class="st-heading-2">What Did The Trial Show?</h2>The Phase 3 TroFuse-005 trial enrolled 776 patients whose endometrial cancer, which affects the lining of the uterus, had progressed following chemotherapy and immunotherapy.Sac-TMT reduced the risk of death by 32% compared with chemotherapy. Patients receiving the drug had a median overall survival of 19 months, compared with 12.1 months with chemotherapy.The treatment also reduced the risk of cancer progression or death by 41%. Median progression-free survival reached 7.2 months, compared with 3.9 months for chemotherapy. Tumors shrank in 35.1% of patients receiving Sac-TMT, compared with 17.3% of patients receiving chemotherapy.<h2 class="st-heading-2">FDA Decision Expected In June 2027</h2>Based on the findings, the U.S. Food and Drug Administration (FDA) accepted Merck’s application for priority review, setting June 15, 2027 as the PDUFA date. The PDUFA date is the regulatory body’s deadline to either approve the drug or issue a complete response letter.Developed with Kelun-Biotech, the treatment is being evaluated in 18 global Phase 3 trials covering endometrial, breast, lung, bladder and other cancers.Separately, Merck reported positive Phase 3 Keynote-C93 results for its blockbuster Keytruda drug as a monotherapy in certain patients with advanced or recurrent endometrial cancer. Keytruda reduced the risk of disease progression or death by 43% compared with chemotherapy.Median progression-free survival was more than four times longer for patients treated with Keytruda as monotherapy compared to chemotherapy.<h2 class="st-heading-2">Retail Calls It ‘Sell The News Event’</h2>Despite today’s fall, retail sentiment on MRK on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/MRK_1_d5aea8a733.png" alt="MRK (1).png">One user called it a “sell the news event.”<stembedurl>https://stocktwits.com/BuyAndHolder/message/667349574</stembedurl>The stock has gained more than 32% so far in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/oruka-psoriasis-treatment-could-generate-7-b-in-peak-sales-says-guggenheim-orka-stock-heads-for-best-day-in-over-4-months/cZU3E1hRByw">&nbsp;Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

The treatment reduced the risk of cancer progression or death by 41%.

In the 776-patient Phase 3 trial, Sac-TMT-treated patients had a median overall survival of 19 months compared to 12.1 months for chemotherapy


Moderna Inc

SPDR S&P Biotech ETF

Track MRK stock price, charts, news and real-time market activity on Stocktwits. Join the MRK message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Merck & Co Inc stock.

MRK Stock Price Today - Merck & Co Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Futures

Fundamentals

Info

MRK Futures

MRK Single Stock Futures